Oral contraceptives and the risk of gallbladder disease: a comparative safety study

被引:38
作者
Etminan, Mahyar [1 ,2 ]
Delaney, Joseph A. C. [3 ]
Bressler, Brian [1 ]
Brophy, James M. [4 ]
机构
[1] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada
[2] Vancouver Coastal Hlth Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada
[3] Univ Florida, Coll Pharm, Gainesville, FL USA
[4] McGill Univ, Fac Med, Dept Med, Montreal, PQ, Canada
关键词
WOMEN; BIAS;
D O I
10.1503/cmaj.110161
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Recent concerns have been raised about the risk of gallbladder disease associated with the use of drospirenone, a fourth-generation progestin used in oral contraceptives. We conducted a study to determine the magnitude of this risk compared with other formulations of oral contraceptives. Methods: We conducted a retrospective cohort study using the IMS LifeLink Health Plan Claims Database. We included women who were using an oral contraceptive containing ethinyl estradiol combined with a progestin during 1997-2009. To be eligible, women had to have been taking the oral contraceptive continuously for at least six months. We computed adjusted rate ratios (RRs) for gallbladder disease using a Cox proportional hazards model. In the primary analysis, gallbladder disease was defined as cholecystectomy; in a secondary analysis, it was defined as hospital admission secondary to gallbladder disease. Results: We included 2 721 014 women in the cohort, 27 087 of whom underwent surgical or laparoscopic cholecystectomy during the follow-up period. Compared with levonorgestrel, an older second-generation progestin, a small, statistically significant in crease in the risk of gallbladder disease was associated with desogestrel (adjusted RR 1.05, 95% confidence interval [CI] 1.01-1.09), drospirenone (adjusted RR 1.20, 95% CI 1.16-1.26) and norethindrone (adjusted RR 1.10, 95% CI 1.06-1.14). No statistically significant increase in risk was associated with the other formulations of oral contraceptive (ethynodiol diacetate, norgestrel and norgestimate). Interpretation: In a large cohort of women using oral contraceptives, we found a small, statistically significant increase in the risk of gallbladder disease associated with desogestrel, drospirenone and norethindrone compared with levo norgestrel. However, the small effect sizes compounded with the possibility of residual biases in this observational study make it unlikely that these differences are clinically significant.
引用
收藏
页码:899 / 904
页数:6
相关论文
共 18 条
[1]
[Anonymous], 2010, LIFELINK HLTH PLAN C
[2]
*CTV INC, 2010, CTV NEWS YASM YAZ BI
[3]
Physical and metabolic factors in gallstone pathogenesis [J].
Donovan, JM .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (01) :75-+
[4]
Complications of cholecystectomy: Risks of the laparoscopic approach and protective effects of operative cholangiography - A population-based study [J].
Fletcher, DR ;
Hobbs, MST ;
Tan, P ;
Valinsky, LJ ;
Hockey, RL ;
Pikora, TJ ;
Knuiman, MW ;
Sheiner, HJ ;
Edis, A .
ANNALS OF SURGERY, 1999, 229 (04) :449-457
[5]
Forrest CB, 2009, AM J MANAG CARE, V15, P41
[6]
GEORGE ED, 2000, CLIN FAM PRACT, V2, P155
[7]
GRODSTEIN F, 1994, OBSTET GYNECOL, V84, P207
[8]
RISK-FACTORS FOR GALLBLADDER-DISEASE - A COHORT STUDY OF YOUNG-WOMEN ATTENDING FAMILY-PLANNING CLINICS [J].
LAYDE, PM ;
VESSEY, MP ;
YEATES, D .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1982, 36 (04) :274-278
[9]
Minimizing Bias Due to Confounding by Indication in Comparative Effectiveness Research The Importance of Restriction [J].
Psaty, Bruce M. ;
Siscovick, David S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (08) :897-898
[10]
Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons [J].
Rosenberg, MJ ;
Waugh, MS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (03) :577-582